Potassium orotate (Potassium orotate)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceOrotic acidOrotic acid
Similar drugsTo uncover
  • Potassium orotate
    pills inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Potassium orotate
    pills inwards 
    AVVA RUS, OJSC     Russia
  • Potassium orotate
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Potassium orotate
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Potassium orotate
    pills inwards 
    PHARMSTANDART-TOMSKHIMFARM, OJSC     Russia
  • Potassium orotate tablets 0.5 g
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
    • Dosage form: & nbsppills
    Composition:

    For one tablet

    Active substance:

    Potassium orotate -500.0 mg /

    Excipients:

    lactose monohydrate 165.0 mg,

    potato starch - 55.0 mg,

    povidone K-17 - 22.5 mg,

    calcium stearate - 7.5 mg.

    Description:Round flat cylindrical tablets of white color with a facet, with a risk on one side.
    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    A.12.C.X   Preparations of other minerals

    Pharmacodynamics:

    The preparation is a potassium salt of orotic acid. Orotic acid is one of the precursors of pyrimidine nucleotides that are part of the nucleic acids that are involved in the synthesis of protein molecules, and therefore the salts of orotic acid are considered as anabolic agents and are used in the disturbances of protein metabolism to stimulate them.Potassium orotate stimulates the synthesis of nucleic acids, the production of albumin in the liver, especially in conditions of prolonged hypoxia (insufficiency of oxygen), increases appetite, has a diuretic (diuretic) and regenerating properties.

    Pharmacokinetics:

    After oral administration in the gastrointestinal tract, 10% of the ingested dose is absorbed (absorbed). In the liver turns into orotidin-5-phosphate. It is excreted by the kidneys (30% in the form of metabolites).

    Indications:

    - In complex therapy as an auxiliary: in diseases of the liver and bile ducts caused by acute and chronic intoxications (with the exception of organic lesions of the liver and bile ducts);

    - with the consequences of malnutrition in children (alimentary and alimentary-infectional malnutrition);

    - in the period of recovery after the transferred diseases;

    - with chronic physical overstrain.

    Contraindications:

    Hypersensitivity to the components of the drug; acute and chronic organic liver damage (including cirrhosis of the liver); ascites (accumulation of fluid in the abdominal cavity); urolithiasis disease; kidney failure; children under 3 years.

    Carefully:

    Pregnancy and lactation.

    Pregnancy and lactation:Carefully.
    Dosing and Administration:

    It should be taken orally 1 hour before meals or 4 hours after meals.

    Adults on 250-500 mg 2-3 times a day. The course of treatment lasts an average of 20-30 days. If necessary, treatment can be repeated after 1 month. AT In exceptional cases, you can increase the dose of adults to 3 grams per day.

    Children - 10-20 mg / kg body weight per day, divided into 3-4 doses (for example, if the child's body weight is 25 kg, then the permitted dose is from 25 x 10 = 250 mg (1/2 tablets) to 25 x 20 = 500 mg (1 table per day, divided into 3-4 doses.) The course of treatment is 3-5 weeks.

    If symptoms persist, consult a physician.

    Side effects:

    Usually, potassium orotate is well tolerated. In some cases, allergic skin reactions may occur, which disappear after the interruption of treatment. Potassium orotate can also cause mild indigestion (nausea, vomiting, diarrhea). When used in high doses against the background of a low protein diet, it is possible to develop liver dystrophy.

    If any side effects occur, consult a doctor.
    Overdose:

    Data on overdose are absent.

    Interaction:

    Astringent and enveloping agents can somewhat reduce the absorption of potassium orotate in the gastrointestinal tract. It is difficult to assimilate iron, tetracycline, sodium fluoride (the interval between taking the drug is at least 2-3 hours). Oral contraceptives, diuretics, muscle relaxants, glucocorticoid agents, insulin reduce the effect of the drug.

    Special instructions:

    During the treatment period it is desirable to follow a diet.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not cause drowsiness and reduce the speed of psychomotor reactions

    Form release / dosage:Tablets, 500 mg.

    Packaging:

    For 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

    2, 5 contour cell packs of 10 tablets with instructions for use are placed in a pack of cardboard.

    Storage conditions:

    In a dry place at a temperature of no higher than 25 ° C in the manufacturer's packaging.

    Keep out of the reach of children.

    Shelf life:

    4 years. Do not use after the expiration date stated on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-001351/08
    Date of registration:29.02.2008 / 09.10.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:UPDATE OF PFC, CJSC UPDATE OF PFC, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspUPDATE OF PFC, CJSCUPDATE OF PFC, CJSC
    Information update date: & nbsp26.11.2017
    Illustrated instructions
      Instructions
      Up